Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

SUBTREAT

Financiado

Subtype as a key to reduce heterogeneity of treatment effects in major depressiv...

Major depressive disorder (MDD) is a leading contributor to disability and suicide. It is the most costly brain disorder in Europe. Although multiple treatments are of proven efficacy, individual responses to treatments vary consi... ver más

30/09/2027

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-03-02

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2021-STG: ERC STARTING GRANTS

I+D

Cerrada hace 3 años

0% 100%

1 Participantes

1.50M€ | Lider

Proyectos interesantes

PID2019-107243RB-C22 EVALUACION COSTE-EFECTIVIDAD DEL TRATAMIENTO PSICOLOGICO TRA... 48K€ Cerrado

PID2020-118582RB-I00 NUEVAS OPCIONES TERAPEUTICAS PARA LA DEPRESION EN LA ADOLESC... 145K€ Cerrado

PRE2020-092381 EVALUACION DE COSTE-EFECTIVIDAD DEL TRATAMIENTO PSICOLOGICO... 99K€ Cerrado

PID2021-125965OB-I00 ESTUDIO DE EFECTIVIDAD Y MECANISMOS DE CAMBIO EN EL TRATAMIE... 72K€ Cerrado

PID2021-125017OB-I00 HACIA UNA COMPRENSION MULTIFACETICA DE LA SALUD MENTAL BASAD... 121K€ Cerrado

RTI2018-093590-B-I00 EFICACIA COADYUVANTE DE UN PROGRAMA MULTIMODAL DE PROMOCION... 48K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 66 meses Fecha Inicio: 2022-03-02
Fecha Fin: 2027-09-30

Líder del proyecto

KAROLINSKA INSTITUTET

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Major depressive disorder (MDD) is a leading contributor to disability and suicide. It is the most costly brain disorder in Europe. Although multiple treatments are of proven efficacy, individual responses to treatments vary considerably and MDD recurrence is common. There is considerable motivation to improve treatment regimen for individuals with MDD. However, it has been challenging because of the fundamental lack of understanding about the causes of variable treatment outcomes. MDD is widely accepted as a heterogeneous disorder; yet, most research strategies effectively consider MDD as a single disorder. Progress in understanding the variable treatment response will depend on patient stratification, i.e., identifying and accounting for patient heterogeneity when evaluating treatment efficacy. SUBTREAT proposes a unique direction which considers subtype as the key to link aetiological and treatment effect heterogeneity. Our approach is to break down the heterogeneous treatment outcomes of MDD into more narrowly defined subtypes with divergent aetiologies. Specially, I propose three work packages: 1) dissect treatment heterogeneity across subtypes; a particularly innovative aspect of SUBTREAT is that we will use advanced data science approaches to identify novel subtypes which correlate with differential treatment outcomes; 2) determine divergent causes underlying MDD subtypes; we will comprehensively investigate causes at three levels including genetic and causal epidemiological risk factors, and brain cell types; 3) develop a novel prediction algorithm for treatment outcomes stratified by patient subgroups. SUBTREAT will illuminate the causes of MDD subtypes and the principal patterns of how subtypes contribute to differential long-term treatment outcomes. SUBTREAT findings will promote targeted drug development and treatment optimization for patient subgroups to achieve precision psychiatry.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores